(Cycloserine + lurasidone hydrochloride) is under clinical development by NRX Pharmaceuticals and currently in Phase III for Bipolar Disorder (Manic Depression). According to GlobalData, Phase III drugs for Bipolar Disorder (Manic Depression) have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Cycloserine + lurasidone hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cycloserine + lurasidone hydrochloride) overview
D-Cycloserine in a fixed dose combination with lurasidone hydrochloride (NRX-101) is under development for the treatment of acute suicidal ideation/behaviour (ASIB) associated with bipolar depression and post traumatic stress disorder. It is administered through oral route as a capsule. The combination is administered as sequential therapy, the treatment begins with a single infusion of NRX-100 (ketamine) followed by approximately six weeks of daily oral administration of NRX-101. D-Cycloserine acts by targeting NMDA receptor and lurasidone hydrochloride targets 5HT2A receptor.
NRX Pharmaceuticals overview
NRX Pharmaceuticals formerly Big Rock Partners Acquisition is a pharmaceutical company developing novel therapies for respiratory disorders. The company is headquartered in Wilmington, Delaware, the US.
For a complete picture of (Cycloserine + lurasidone hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.